Xishan Technology Secures Over RMB 100 Million Series D Financing to Advance as a Global Leader in Minimally Invasive Surgical Devices

VCBeat (WeChat ID: vcbeat) recently learned that Chongqing Xishan Science&Technology Co.,Ltd. (hereinafter referred to as “Xishan Technology”) announced the completion of its Series D strategic financing round, exceeding RMB 100 million, led by industrial investorsSinopharm Investment, Jinhe CapitalJointly accomplished. The proceeds from this round of financing will be used for new product research and development, clinical study registration, and market commercialization, continuously building a leading brand in minimally invasive medical devices that is first-class in China and internationally advanced.

Minimally invasive surgical medical devices have emerged as a high-growth “golden track” within the medical device industry over the past decade. After three decades of imports of mid-to-high-end medical technologies and device products from developed countries, China has formed an existing market dominated by imported products, characterized by strong monopolistic patterns. Recognizing the importance of domesticating high-end manufacturing, China is vigorously promoting import substitution for medical devices, leveraging its demographic dividend of engineers and locational advantages. With the booming development of minimally invasive medical technologies, there is substantial market demand for minimally invasive surgical tools such as powered systems, endoscopes, and energy-based devices.

Established in 1999, Xishan Technology is a high-tech enterprise integrating the research and development, manufacturing, and sales of software and hardware for minimally invasive surgical medical devices. The company’s main products are strategically arranged around three major technology platforms and seven business directions, including surgical power equipment and consumables for departments such as neurosurgery, otolaryngology, orthopedics, and breast surgery. Since its inception, the company has focused on technical research and product development centered on surgical navigation and surgical treatment, building a “1+2” product portfolio. Always adhering to the mission of “empowering physicians and facilitating patient recovery,” Xishan Technology is committed to becoming a world-class brand in minimally invasive medical devices.

Meanwhile, the company is a National Intellectual Property Demonstration Enterprise and a recipient of the “China Patent Excellence Award.” It independently controls multiple core technologies and key manufacturing processes, with more than 900 patent applications filed. Reportedly, Xishan Technology places great emphasis on R&D investment, which has accounted for over 10% of its revenue in each of the past three years. Many of its technologies are industry-leading, and it has served as the primary drafter for numerous pharmaceutical and medical industry standards. Currently, Xishan Technology has become a leading enterprise in the niche segment of minimally invasive surgical medical devices.

Guo Yijun, Chairman of Chongqing Xishan Science&Technology Co.,Ltd.He stated, “We extend our gratitude to Sinopharm Investment and Jinhe Capital for their support and encouragement of Xishan Technology. With the assistance of these two industrial investors, we are confident that Xishan Technology will adhere to its strategic positioning as a ‘comprehensive provider of minimally invasive surgical instrument solutions,’ achieve rapid development, scale new heights, and contribute to the localization of minimally invasive surgical instruments in China.”

Zhang Weiya, Head of the Industrial Investment Department at Sinopharm CapitalIt stated: “China’s market for minimally invasive surgical instruments is in a period of rapid growth. As an important component of this market, the surgical power system industry is characterized by high capital investment, long R&D cycles, and high competitive barriers. Chongqing Xishan Science&Technology Co.,Ltd. has mastered core technologies such as motors and precision cutting tools, with its product quality and portfolio ranking among the top tier of domestic surgical power systems. Sinopharm Capital is optimistic about Xishan Technology’s development in the field of minimally invasive surgery. Following this strategic investment, it will fully leverage the whole-industry-chain platform resources of Sinopharm Group to continuously empower Xishan Technology, support the development of domestic brands, and accelerate the process of import substitution in the field of minimally invasive surgery.”

Mr. Hao Bixi, Co-Founder of Jinhe Capital“It is indicated that the Chinese market for minimally invasive surgical instruments is experiencing rapid growth, presenting significant opportunities for import substitution. The management team of Chongqing Xishan Science&Technology Co.,Ltd. combines keen market insight with strategic layout capabilities, and its independently developed product series has received high recognition from clinical experts, placing the company at the forefront of the industry in terms of comprehensive strength. Jinhe Capital is highly optimistic about Xishan Technology’s profound technical foundation and its platform-oriented development strategy. Following this strategic investment, we will fully integrate industrial resources to continuously empower Xishan Technology, helping the enterprise become a nationally recognized Chinese brand with greater industry prominence.”

Sinopharm Capital, also known as China Pharmaceutical Investment Co., Ltd., is a wholly-owned subsidiary of China National Pharmaceutical Group Corporation (abbreviated as “Sinopharm”). With a registered capital of RMB 3 billion, the company managed assets exceeding RMB 38 billion in 2020. Guided by its strategic positioning as “a professional investment company specializing in the pharmaceutical and healthcare industry, with a global perspective, industry focus, and commitment to serving the Group,” Sinopharm Capital concentrates on financial services and equity investments in health-related sectors. It places particular emphasis on industrial M&A and supply chain integration, as well as technological and business model innovation. The company aims to establish an investment development model with distinct Sinopharm characteristics and strives to become an internationally influential pharmaceutical and healthcare investment company with significant impact and driving force.

Jinhe Capital is an investment firm focused on the healthcare sector, headquartered in Guangzhou. The core team of its fund manager possesses over 25 years of experience in the medical industry and successfully established KingMed Diagnostics, China’s largest third-party medical testing laboratory. Jinhe Capital currently manages two healthcare industry funds with a combined scale of nearly RMB 2 billion. The firm continues to make strategic investments in areas such as in vitro diagnostics (IVD), innovative medical devices, and life sciences, actively building an industrial ecosystem. It is committed to leveraging the synergy between industry expertise and capital to cultivate healthcare enterprises with international competitiveness.